TY - JOUR
T1 - A structurally minimized yet fully active insulin based on cone-snail venom insulin principles
AU - Xiong, Xiaochun
AU - Menting, John G.
AU - Disotuar, Maria M.
AU - Smith, Nicholas A.
AU - Delaine, Carlie A.
AU - Ghabash, Gabrielle
AU - Agrawal, Rahul
AU - Wang, Xiaomin
AU - He, Xiao
AU - Fisher, Simon J.
AU - MacRaild, Christopher A.
AU - Norton, Raymond S.
AU - Gajewiak, Joanna
AU - Forbes, Briony E.
AU - Smith, Brian J.
AU - Safavi-Hemami, Helena
AU - Olivera, Baldomero
AU - Lawrence, Michael C.
AU - Chou, Danny Hung Chieh
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Human insulin and its current therapeutic analogs all show propensity, albeit varyingly, to self-associate into dimers and hexamers, which delays their onset of action and makes blood glucose management difficult for people with diabetes. Recently, we described a monomeric, insulin-like peptide in cone-snail venom with moderate human insulin-like bioactivity. Here, with insights from structural biology studies, we report the development of mini-Ins—a human des-octapeptide insulin analog—as a structurally minimal, full-potency insulin. Mini-Ins is monomeric and, despite the lack of the canonical B-chain C-terminal octapeptide, has similar receptor binding affinity to human insulin. Four mutations compensate for the lack of contacts normally made by the octapeptide. Mini-Ins also has similar in vitro insulin signaling and in vivo bioactivities to human insulin. The full bioactivity of mini-Ins demonstrates the dispensability of the PheB24–PheB25–TyrB26 aromatic triplet and opens a new direction for therapeutic insulin development.
AB - Human insulin and its current therapeutic analogs all show propensity, albeit varyingly, to self-associate into dimers and hexamers, which delays their onset of action and makes blood glucose management difficult for people with diabetes. Recently, we described a monomeric, insulin-like peptide in cone-snail venom with moderate human insulin-like bioactivity. Here, with insights from structural biology studies, we report the development of mini-Ins—a human des-octapeptide insulin analog—as a structurally minimal, full-potency insulin. Mini-Ins is monomeric and, despite the lack of the canonical B-chain C-terminal octapeptide, has similar receptor binding affinity to human insulin. Four mutations compensate for the lack of contacts normally made by the octapeptide. Mini-Ins also has similar in vitro insulin signaling and in vivo bioactivities to human insulin. The full bioactivity of mini-Ins demonstrates the dispensability of the PheB24–PheB25–TyrB26 aromatic triplet and opens a new direction for therapeutic insulin development.
UR - http://www.scopus.com/inward/record.url?scp=85085878153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085878153&partnerID=8YFLogxK
U2 - 10.1038/s41594-020-0430-8
DO - 10.1038/s41594-020-0430-8
M3 - Article
C2 - 32483339
AN - SCOPUS:85085878153
SN - 1545-9993
VL - 27
SP - 615
EP - 624
JO - Nature Structural and Molecular Biology
JF - Nature Structural and Molecular Biology
IS - 7
ER -